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ABSTRACT
Objective: To determine which parameter is the most
useful screening test for hypothalamic–pituitary–
adrenal suppression in asthmatic children.
Design: Cross-sectional study.
Setting: Paediatric allergy clinics in Cape Town, South
Africa.
Participants: 143 asthmatic children of mostly mixed
ancestry, aged 5–12 years.
Outcome measures: Primary outcome measures
included Spearman correlation coefficients (r) calculated
between the postmetyrapone (PMTP) serum
adrenocorticotropic hormone (ACTH), 11-deoxycortisol
(11DOC), 11DOC+ cortisol (C) and height, weight, height
velocity, weight velocity, change in systolic blood pressure
from supine to standing, early morning urinary free cortisol
(UFC), morning C, ACTH and dehydroepiandrosterone
sulfate (DHEAS). Secondary outcome measures were the
receiver operating characteristics (ROC) curve and the
diagnostic statistics for the most promising test.
Results: All screening variables were weakly correlated
with the three PMTP outcomes. Only DHEAS and UFC
(nmol/m2) were statistically significant—DHEAS for
PMTP ACTH and 11DOC (r=0.20, p=0.025 and r=0.21,
p=0.017); UFC (nmol/m2) for PMTP 11DOC and
11DOC+C (r=0.19, p=0.033 and r=0.20, p=0.022). The
area under ROC curve for DHEAS in the 5-year to 9-year
age group was 0.69 (95% CI 0.47 to 0.92). At DHEAS
cut-off of 0.2 µmol/L: sensitivity=0.88 (CI 0.47 to 1.00),
specificity=0.61 (CI 0.42 to 0.78), positive predictive
value=0.37 (CI 0.16 to 0.62), negative predictive
value=0.95 (CI 0.75 to 1.00), accuracy=0.67 (CI 0.50 to
0.81), positive likelihood ratio=2.26 (CI 1.35 to 3.78),
negative likelihood ratio=0.20 (CI 0.03 to 1.30).
Conclusions: No parameter is useful as a universal
screening test. DHEAS may be suitable to exclude HPAS
before adrenarche. Further research is needed to
confirm these findings and identify factors, for example,
genetic that may predict or protect against HPAS.
INTRODUCTION
Recently, two-thirds of asthmatic children
treated with corticosteroids (CS) in allergy
units in South Africa were found to have a
degree of hypothalamic–pituitary–adrenal
(HPA) axis dysfunction, while the pituitary/
ARTICLE SUMMARY
Article focus
▪ Two-thirds of asthmatic children treated with
corticosteroids (CS) in allergy units in Cape
Town, South Africa were found to have a degree
of hypothalamic–pituitary–adrenal axis (HPA)
dysfunction, while the pituitary/hypothalamus
and the adrenals were suppressed in 16% of
cases.
▪ It has been claimed that static adrenal function
tests such as serum cortisol, adrenocorticotropic
hormone (ACTH), dehydroepiandrosterone
sulfate (DHEAS) and urinary free cortisol (UFC)
are useful to document HPA suppression (HPAS)
in asthmatic children on CS.
▪ This study was performed to detect the most
suitable screening test by comparing several
clinical and biochemical candidate tests with the
overnight metyrapone test.
Key messages
▪ No clinical or static biochemical parameter is a
universally useful screening test for HPAS in
asthmatic children of all ages.
▪ Serum DHEAS may be of limited use prior to
adrenarche.
Strengths and limitations of this study
▪ To the best of our knowledge, this is the largest
study ever which analyses the usefulness of
various candidate screening tests for HPAS.
▪ Contrary to common belief, it highlights the
limited utility of UFC and DHEAS, both of which
are frequently claimed to be helpful in detecting
HPAS.
▪ As the study was powered to establish the diag-
nostic performance of the early morning serum
ACTH, age-specific subgroups for an appropriate
DHEAS analysis were rather small, thus limiting
the usefulness of the latter analysis.
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hypothalamus and the adrenals were suppressed in only
16% of cases.1 Clinical features suggestive of adrenal
insufﬁciency (AI) were only seen in some hypocortiso-
laemic children. This conﬁrms the notion that HPA sup-
pression (HPAS) is largely subclinical.2 In the allergy
clinic setting, it is rather cumbersome and impractical to
detect these by dynamic adrenal function tests. A suit-
able screening test should thus be sought. To qualify,
strict criteria pertaining to the potential candidate, the
disease and the intervention policy should be fulﬁlled.3 4
The latter two requirements are easily met.5 Whether a
simple, safe, valid and reliable screening test with an
appropriate cut-off can be found is another matter.
Proposed clinical candidates such as height velocity
(HV), or basal adrenal function tests, for example, dehy-
droepiandrosterone sulfate (DHEAS), urinary free corti-
sol (UFC) or urinary cortisol metabolites, whether as
24 h, spot or early morning urine collection, have been
investigated and found to be unsatisfactory.5 The theor-
etical limitations of the latter have previously been dis-
cussed in detail.2 Yet, conclusive remarks about HPA
function are still based on static biochemical parameters
in numerous clinical trials.6–10 The early morning adre-
nocorticotropic hormone (ACTH) has been identiﬁed
as a possible useful screening test in a recent pilot
study.5 However, ACTH’s short plasma half life
(<10 min) should have rendered it unsuitable.11 The
area (AUC) under the receiver operating characteristics
(ROC) curve for the morning serum ACTH, when com-
pared to the overnight metyrapone test (ONMTPT) was
0.83 (95% CI 0.65 to 1.00)), classifying it as a good test.
Its utility, however, has to be conﬁrmed, as the sample
size was small (n=26). A larger cross-sectional study,
including children with and without HPAS, was thus
undertaken to determine which clinical or static bio-
chemical parameter is the most useful screening test for
HPAS in this setting.
PARTICIPANTS AND METHODS
A total of 143 asthmatic children, on inhaled CS (ICS)
with or without additional CS therapy, were recruited
from the allergy clinics of Tygerberg Children’s
Hospital, Red Cross Children’s Hospital and the Lung
Institute. Every eligible patient ≥11 years and every
second eligible patient <11 years was included. Asthma
was diagnosed clinically by a doctor, based on symptoms
and reversible airway obstruction.12 All children had per-
sistent asthma, and those who were known to have HPA
dysfunction, untreated hypothyroidism or liver disease
and who were treated with phenobarbitone, phenytoin,
rifampicin, amytryptyline, chlorpromazine, neomerca-
zole or hormone replacement therapy were excluded.
Height, weight and change in systolic blood pressure, as
measured with an electronic blood pressure measuring
device by the research assistant, were recorded. The
annualised HV and weight velocity (WV) were calculated
by extracting the height and weight data of 1 year earlier
from the records. The following growth standards were
utilised: the UK 1990 weight and height standards, the
UK 1966 HV standards and the Gerver 2001 WV stan-
dards. Anthropometric measurements and velocities
were recorded as SD scores (SDS). The ﬁrst voided early
morning urine (06:00–07:00 h) for UFC was collected.
The results were expressed both in nmol/m2 body
surface area and in nmol/mmol creatine (Cr). Fasting
blood between 08:00 and 09:00 for cortisol (C), ACTH
and dehydroepiandrosterone sulfate (DHEAS) was
taken. The ONMTPT was performed according to pub-
lished protocol,13 if the fasting morning serum C was
>83 nmol/L. The rationale for its use and the cut-offs
have been explained previously.1 2 An adequate response
was deﬁned by a rise of ACTH from baseline to
>106 pg/mL (23.3 pmol/L),14 an 11-deoxycortisol
(11DOC) rise to >208 nmol/L15 or a 11DOC+C rise to
>400 nmol/L.15 16 The ONMTPT was not performed on
all participants, as the risk of precipitating an adrenal
crisis during the performance of test is higher when the
child is already hypocortisolaemic. Furthermore, frank
hypocortisolaemia, implying that basal C production is
impaired, would render dynamic testing superﬂuous. As
the assays used in this study were different from the
assays in the original description, the published cut-offs
were modiﬁed by correlation studies, performed either
in-house (11DOC) or by the manufacturer (ACTH).
The readers of the tests were blind to all other results.
The study was approved by the ethics committees of
both universities. The investigators complied with the
World Medical Association Declaration of Helsinki
regarding ethical conduct of research involving human
subjects. The study was funded by the Medical Research
Council, the University of Stellenbosch, the South
African Thoracic Society, the Harry Crossley Foundation
and Red Cross Children’s Hospital. No additional infor-
mation is available.
Assays
Serum C and UFC was measured with the ADVIA auto-
mated chemiluminescent assay. The analytical sensitivity
was 5.5 nmol/L. At 107.05 nmol/L the intra-assay CV was
3.69% while the inter-assay CV was 5.45%. No cross-
reactivity to ﬂuticasone, budesonide, beclomethasone or
prednisone is known. ACTH was measured with an auto-
mated sequential chemiluminescent immunometric assay
(Immulite 2000). Its analytical sensitivity was 5 pg/mL
(1.1 pmol/L), while the precision at 23 pg/mL (5 pmol/L)
ranged from 8.7% (within run) to 10% (run-to-run). No
cross-reactivity has been reported. At the end of the
study, levels of serum 11DOC were established by a single
experienced person, utilising the Biosource competitive
radioimmunoassay. Its analytical sensitivity was 0.1 nmol/L.
Only 0.1% cross-reactivity with C has been reported. The
intra-assay CV at 82 nmol/L was 7.8% and the inter-assay
CV at 95 nmol/L was 14.1%. DHEAS levels were deter-
mined by an automated electrochemiluminescence
immunoassay (Modular Analytics E170) with an
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analytical sensitivity of 0.003 µmol/L. The lower limit of
the analyser was set at 0.1 µmol/L. At a mean of
2.6 µmol/L the intra-assay CV was 3.2%, while the inter-
assay CV was 2.5% at a mean 2.5 µmol/L. The CVs were
2.6% and 2.7%, respectively, for means of 10.9–
10.7 µmol/L. There was no signiﬁcant cross-reactivity.
Statistical analysis
On the basis of a pilot study (n=26), a sample size of
100 was calculated to be sufﬁcient to halve the CI of
0.57 to 0.98 for the sensitivity (0.89) of the morning
ACTH. Growth velocities were analysed by Growth
Analyser, V.3.5. Spearman correlations (r) were calcu-
lated between the postmetyrapone (PMTP) ACTH,
11DOC, 11DOC+C and each proposed screening vari-
able. Based on the most signiﬁcant Spearman correla-
tions, ROC analysis was performed. Using the probit
model and maximum likelihood estimation, a paramet-
ric ROC regression analysis of DHEAS screening on
HPAS was carried out and two covariates, age and sex,
were adjusted for. The effect sizes from the ROC regres-
sion model can be interpreted as the standardised linear
effects of the covariates on HPAS. ROC curves were
drawn for the best model and the sensitivity, speciﬁcity,
positive/negative predictive values, accuracy, positive and
negative likelihood ratios (LRs) were calculated for the
optimal cut-off between sensitivity and speciﬁcity.
Analyses were carried out in STATA and R,17 the freely
available environment for graphics and statistics. The
score method was used to calculate the CIs of the LRs.
RESULTS
The study ran from July 2008 until June 2010 (tables 1
and 2). The ONMTPT was performed 2–3 weeks after
the morning samples were obtained. Asthma therapy
remained the same during this period, except in two
cases which were excluded. ONMTP was repeated in two
patients who vomited after administration of MTP.
During the analysis, outliers were not excluded, but
participants with missing values were. After adjusting for
age, using ANOVA, no centre difference on log ACTH
(p=0.105) and log (DHEAS+0.22) (p=0.543) could be
demonstrated.
The prevalence of HPAS was previously reported.1
Only serum DHEAS and UFC (nmol/m2) were statistical
signiﬁcantly correlated with the postmetyrapone
(PMTP) ACTH, 11DOC and 11DOC+C (table 3). As
normal DHEAS values are known to vary with age and
gender, further analysis of DHEAS measurements were
carried out for the same subgroups in which normal
values had been established by Roche (table 4). A ROC
regression analysis of DHEAS revealed a signiﬁcant age
and sex effect on HPAS. The effect sizes for age were
−1.62 (p=0.006) for the 10-year-old to 14-year-old chil-
dren and−3.59 (p<0.001) for the 15-year-old to
19-year-old children. This implies that these age groups
make a negative contribution to the ROC curve. The
effect size for gender was 1.19 (p=0.024), implying that
gender makes a positive contribution to the ROC curve.
As the subgroups of the study were rather small and as it
is known that the normal reference range of DHEAS
prior to onset of adrenarche is the same for boys and
girls, the gender categories were pooled to obtain a
larger sample per age group. The derived smoothed
ROC curves showed a clear separation between the age
groups, conﬁrming the age effect (ﬁgure 1). The AUC
for the crude ROC curve of the only promising age
group, the 5-year-olds to 9-year-olds, was 0.69 (CI 0.47 to
Table 1 Demographics and therapy
Total n 143
Male:female 77:66
Age (range) 11* (5.2–17.5) years
Ethnic group Mixed ancestry 138
Caucasian 4
African 1
Asthma score† 1.43* (0.14–4.14)
ICS and device BUD Hfa MDI and spacer 128
BUD Hfa MDI 11




BUD equivalent 439* (108–1058) µg











BUD equivalent 118* (54–468) µg




















n on steroid eye
drops (% of total)
4/143 (3)
Steroid eye drops Fluoromethalone 3
Dexamethasone 1
*Median.
†As established by Asthma Control Questionnaire.
‡80 µg BUD is comparable to 1 mg HC in potency.
§1 mg prednisone equates to 4 mg HC in potency.
BUD, budesonide; BDP, Beclomethasone diproprionate; DPI, dry
powder inhaler; FP, fluticasone proprionate; HFA,
hydrofluroalkane; HC, hydrocortisone; ICS, inhaled corticosteroids;
MDI, metered dose inhaler; NS, Nasal steroids; OCS, oral
corticosteroids (prednisone) given for maintenance or
exacerbation (ONMTPT performed while on OCS); TS, topical
steroids.
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0.92; ﬁgure 2). The best discrimination between those
with HPAS (sensitivity of 0.88) and those without HPAS
(speciﬁcity of 0.61) for this age group is a DHEAS value
of 0.2 µmol/L. The diagnostic performance at this point
is given in table 5.
The AUC for the ROC curve of the UFC (nmol/m2)
compared to the PMTP 11DOC was only 0.57 (CI 0.47
to 0.67). This improved slightly to 0.63 (CI 0.53 to 0.72)
when the outcome of the gold standard test was
changed to the PMTP 11DOC+C. Adding DHEAS and
UFC (nmol/m2) to a logistic regression model for
HPAS, previously described,1 did not improve the
model. The OR for DHEAS and UFC (nmol/m2) were
0.72 (CI 0.33 to 1.26) and 1.00 (CI 0.99 to 1.01)
respectively.
DISCUSSION
The results of the pilot study (n=26)5 in which the early
morning serum ACTH was moderately and signiﬁcantly
correlated (r=0.68; p<0.001) to the PMTP ACTH, could
not be conﬁrmed in the present study. This may be the
result of studying a larger sample (n=143) with
increased heterogeneity. As explained above, a single
serum ACTH level is unlikely to be a valid indicator of
HPAS11 and hence does not fulﬁl the criteria for a
screening test.3 4 A valid screen should be able to distin-
guish between patients who do and those who do not
have HPAS. “Furthermore, it should be cost-effective,
easy to perform, safe, reliable and the cut-off value
between pathology and normality should be reasonably
well deﬁned.”5 As indicated by signiﬁcant Spearman cor-
relations, it is only the serum DHEAS and UFC (nmol/
m2) that need further consideration as screening tests.
It is clear from the ROC regression model that serum
DHEAS is not a useful screening tool in the 10–14 and
the 15-year to 18-year age groups. The AUC of the ROC
curve for the 5-year-olds to 9-year-olds is similar to the
one published recently,6 although in the latter, a sub-
group analysis was not performed. At best it is a fair
screening test in the younger age group. The pretest
probability (prevalence) of HPAS is known to be 16%.1
At a diagnostic cut-off of 0.2 µmol/L, the post-test prob-
ability, given a lower DHEAS level, would rise to 30%
(CI 21 to 42%) if the serum DHEAS is utilised as a
screening test (refer to the positive LR in table 4). With
a DHEAS measurement above 0.2 µmol/L (see negative
LR in table 4), the post-test probability would drop to
Table 3 Spearman correlations between PMTP ACTH, 11DOC, 11DOC+C and screening variables
Screening variable
ACTH 11DOC 11DOC+C
r p Value r p Value r p Value
Height SDS 0.12 0.186 −0.13 0.120 −0.05 0.542
Weight SDS 0.10 0.262 −0.01 0.195 −0.10 0.279
HV SDS 0.00 0.999 0.07 0.420 0.07 0.452
WV SDS −0.04 0.638 0.07 0.421 0.09 0.302
ΔSBP 0.00 0.992 0.05 0.538 −0.04 0.616
Morning C 0.05 0.538 0.08 0.374 0.12 0.176
Morning ACTH 0.10 0.248 0.04 0.640 0.10 0.263
DHEAS 0.20 0.025* 0.21 0.017* 0.00 0.995
UFC (nmol/m2) 0.08 0.379 0.19 0.033* 0.20 0.022*
UFC (nmol/mmol Cr) 0.08 0.397 0.14 0.111 0.16 0.064
*Significant, p<0.05.
ACTH, adrenocorticotropic hormone; C, Cortisol; DHEAS, dehydroepiandrosterone sulphate; HV, height velocity; PMTP, post-metyrapone;
ΔSBP, change in systolic blood pressure; UFC, urinary free cortisol; WV, weight velocity; 11DOC, 11-deoxycortisol.


















129/143 (90.2) Inadequate serum
volume
Screening variables




HV SDS 132/143 (92.3) Missing data
WV SDS 139/143 (97.2) Missing data





Morning C 142/143 (99.3) Transcription error
UFC 128/143 (89.5) Samples leaked in
transit
DHEAS 127/143 (88.8) Samples stored
>2 months
ACTH, adrenocorticotropic hormone; C, Cortisol; DHEAS,
dehydroepiandrosterone sulfate; HV, height velocity; PMTP,
postmetyrapone; 11DOC, 11-Deoxycortisol; ΔSBP, change in
systolic blood pressure; UFC, urinary free cortisol; WV, weight
velocity.
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3.7% (CI 0% to 20%). Thus, serum DHEAS levels seem
to be more useful in ruling out HPAS (see negative pre-
dictive value in table 4) than predicting it. A DHEAS
level may hence not qualify as a useful screen, bearing
in mind that this conclusion is based on a small sample
size.
Serum DHEAS has repeatedly been touted in the lit-
erature as a useful screening tool for central AI18 19 or
for HPAS in asthmatics treated with ICS.6 7 20–22 In one
study, it was claimed that the serum DHEAS is a ‘prac-
tical surrogate measurement’ to identify asthmatic
children at risk of HPAS.6 However, only 22 patients of
unknown age and gender were enrolled. DHEAS levels
were not compared to a gold standard adrenal function
test. Results were presented in SDS which is problematic,
as normal DHEAS measurements do not follow a
Gaussian distribution. The limitations of this study
prompted us to look at the DHEAS performance in our
study, even though it was not powered to do this. Clearly,
even a sample of 40 in our 5-year to 9-year age group is
too small for an optimal and conclusive study (table 4).
Each subgroup would have required 50–100 children.
Whether one should embark on a larger study to
ascertain the diagnostic capability of serum DHEAS in
the ‘pre-adrenarchal’ age group, is debatable.
Presumably, the cost and effort of such an undertaking
do not outweigh the beneﬁt. Clearly, serum DHEAS is
not a useful screening test in the older paediatric age
groups where normal levels are known to vary with age,
gender and Tanner stage.23 There are similar limitations
seen in adults with central AI, although it is claimed its
accuracy is 100% in patients <30 years (n=11), and, that
it performs better in patients with pituitary macroadeno-
mas (n=31).18 In patients without pituitary adenomas
(n=35), the AUC of ROC curve was 0.71—similar to the
AUC established in this study.
Figure 1 Predicted ROC curves (from a ROC regression
model) of DHEAS versus HPAS by age.




5–9 10–14 15–18 Total
Males
No HPAS 18 32 9 59
HPAS 2 6 2 10
Total 20 38 11 69
Females
No HPAS 14 25 9 48
HPAS 6 3 1 10
Total 20 28 10 58
Total
No HPAS 32 57 18 107
HPAS 8 9 3 20
Total 40 66 21 127
*Postmetyrapone ACTH<106p/mL (23.3 pmol/L) AND
11DOC<208 nmol/L AND 11DOC+C<400 nmol/L.
DHEAS, dehydroepiandrosterone sulphfate; HPAS, hypothalamic–
pituitary–adrenal suppression.
Figure 2 ROC curve of DHEAS versus HPAS for 5–9 year old
age group. Area under ROC curve=0.69 (95% CI: 0.47–0.92).
Table 5 Diagnostic performance of DHEAS, at 0.2 µmol/
L, for 5-year-old to 9-year-old age group
Index of test validity Value 95% CI
Sensitivity 0.88 0.47 to 1.00
Specificity 0.61 0.42 to 0.78
Positive predictive value 0.37 0.16 to 0.62
Negative predictive value 0.95 0.75 to 1.00
Accuracy 0.67 0.50 to 0.81
Positive likelihood ratio 2.26 1.35 to 3.78
Negative likelihood ratio 0.20 0.03 to 1.30
DHEAS, dehydroepiandrosterone sulfate.
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In adulthood, the average DHEAS levels are much
higher (about 10 µmol/L).24 Thus, determined by adult
requirements, analysers have been calibrated at a lower
limit which is higher than the analytical sensitivity of the
assay. It is unlikely that large scale recalibrations will be
performed outside the research setting in order to
accommodate readings in the nmol/L range for the
‘pre-adrenarchal’ age group,13 thereby limiting its use-
fulness as a screening tool for this age. Furthermore,
ACTH is not the sole stimulus of DHEAS release.
Fragments of proopiomelanocortin,24 insulin-like growth
factor one (IGF-1) and insulin25 also seem to be playing
a role. DHEAS levels are therefore unsuitable candidates
on theoretical grounds.
UFC is known to be useful in the setting of C excess,
but not in C deﬁciency. Its usefulness as a screening test
is limited by physiology and the design of the assay.2 5
Under normal circumstances, most C is bound to corti-
sol binding globulin with only <1% of free C being
excreted in the urine, making it difﬁcult to distinguish a
C deﬁcient from a C sufﬁcient state. The proportion of
free C in the urine rises substantially as the serum total
C increases to ≥690 nmol/L. One could argue that it
would have been more appropriate to collect a 24 h
urine sample in order to correctly reﬂect the daily pro-
duction of C. This is, however, not the purpose of a
screening test and would be impractical, especially in
children. Furthermore, all the limitations would apply,
irrespective of volume and duration of collection. We
would thus not encourage the use of any screen based
on UFC, as it is extremely unlikely to accurately predict
which child will appropriately respond to stress.
We did not assess salivary free C, because its limita-
tions are similar to those of the UFC, its lower limit of
normal being close to zero, making an assessment of
HPAS difﬁcult.2 Furthermore, salivary free C, like serum
C and ACTH, is subjected to ultradian and circadian
rhythms which could be modiﬁed by season, puberty,
exercise and stresses. Like UFC, salivary free C is more
useful in diagnosing Cushing’s syndrome, by demonstrat-
ing loss of diurnal variability.
The route, mode or relative contribution of the
various forms of inhibiting CS (table 1) is of no conse-
quence in the quest for suitable screening tests for
HPAS. Nonetheless, it has been established that, of the
CS used, only ICS and nasal CS contributed signiﬁcantly
to the suppression.1 Oral CS courses for exacerbations
did not correlate to HPAS.1
HPAS already occurred at combined ICS and nasal CS
doses equivalent to the normal C production rate of
3–10.6 mg/m2/day (equivalent to budesonide 240–
848 µg/m2/day), thus challenging the perception that a
ﬂuticasone propionate dose of <400 µg/day (budesonide
dose <800 µg/day), based on 12 h UFC26 is less suppres-
sive than at higher doses.1
Continuing the search for a suitable screening test to
detect HPAS is at this point unlikely to be successful. One
can only attempt to predict which asthmatic children on
CS are likely to develop HPAS.1 Alternatively, a search for
mutations or gene polymorphisms which determine the
interindividual variation at various levels of the HPA
should be undertaken.27–30 This may provide the best way
to predict which asthmatic child would be predisposed to
or protected against HPAS.
CONCLUSIONS
No clinical or static biochemical parameter could be
identiﬁed as a suitable screening test for HPAS in asth-
matic children of all ages. Serum DHEAS levels may
only be useful to rule out HPAS in children prior to
adrenarche.
We therefore discourage the use of any basal adrenal
function test. Any researcher who plans to utilise the
serum DHEAS level as a screen in the 5-year-old to
9-year-old age group, needs to document its diagnostic
performance in a large study ﬁrst. Further research is
needed to identify genetic factors that might predict or
protect against HPAS.
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